Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

NCT01712490 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT01712490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
November 9, 2012
Completion date
February 2, 2026
Enrollment
1,334 (actual)
Sites
215

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma